169277 ⎘
Investigating or analysing materials by specific methods not covered by groups -; Biological material, e.g. blood, urine ; Haemocytometers; Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing; Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
COMPOSITIONS AND METHODS TO DETECT HEAD AND NECK CANCER
#2SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#3BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
#4AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#5ANTI-MUTATED KRAS T CELL RECEPTORS
#6HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS
#7PRAME IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING PRAME IMMUNOGENIC PEPTIDES, AND USES THEREOF
#8FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN
#9PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#10TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
#11CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
#12A METHOD FOR DETECTING CLUSTERING OF RAS PROTEIN
#13Camelid/Llama Nanobodies to Target WNT16B as a Chemotherapy Option for Cancer Treatment
#14USE OF TCTP AS BIOMARKER FOR PREDICTING EFFICACY, PROGNOSIS OF IMMUNOTHERAPY OR RESISTANCE THERETO, AND TARGET OF IMMUNOTHERAPY FOR ENHANCING EFFICACY
#15CHARGED MASS LABELING SYSTEM
#16HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-2 AND USES THEREOF
#17Detection of anti-p53 antibodies
#18CELLS EXPRESSING HER3 ANTIGEN-BINDING MOLECULES
#19PRODUCT AND PROCESS FOR EMPLOYING GC7 (N1-GUANYL-1,7-DIAMINOHEPTANE) BASED ANTIGEN BINDING CONJUGATES IN CANCER THERAPY
#20METHODS BASED ON THE DETECTION OF RAD51 FOCI IN TUMOR CELLS
#21HER3-BINDING ANTIBODY-DRUG CONJUGATE
#22ANTICANCER THERAPY
#23HER2 VACCINE COMPOSITION
#24BIOMARKER FOR DIAGNOSIS, TREATMENT, AND PROGNOSIS FOR HEPATOCELLULAR CARCINOMA BONE METASTASIS AND APPLICATION THEREOF
#25ANTI-KIT ANTIBODIES AND USES THEREOF
#26COMPOSITIONS AND METHODS TO DETECT HEAD AND NECK CANCER
#27MONOCLONAL ANTIBODIES AGAINST C-MET
#28Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
#29T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS
#30BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND APPLICATIONS THEREOF
#31BIOMARKERS FOR CBL, AND COMPOSITIONS AND METHODS FOR THEIR USE
#32TEST METHOD, OF DIVIDING BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM (BPDCN) INTO SUBTYPES
#33BIOMARKERS FOR CANCER THERAPY USING MDM2 ANTAGONISTS
#34ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER
#35Polypeptide-antibody complexes and uses thereof
#36HLA CLASS II-RESTRICTED DRB T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION
#37COMPOSITIONS AND METHODS FOR IDENTIFICATION OF MODULATORS OF RAS PROTEIN COMPLEXES
#38Method for Predicting Effectiveness of Angiogenesis Inhibitor
#39HISTOCHEMICAL SYSTEMS AND METHODS FOR EVALUATING EGFR AND EGFR LIGAND EXPRESSION IN TUMOR SAMPLES
#40HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION
#41Diagnostic and therapeutic methods for cancer
#42SYSTEM FOR DETECTING INFECTION IN SYNOVIAL FLUID
#43BCR-ABL TRUNCATION MUTATIONS
#44Claudin-6 antibodies and drug conjugates
#45PHOSPHORYLATED AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#46METHODS FOR DETERMINING THE INVASIVE AND/OR METASTATIC POTENTIAL OF A TUMOUR
#47METHOD FOR DETERMINING PRESENCE OR ABSENCE OF RISK OF DEVELOPING CANCER
#48T CELL RECEPTORS RECOGNIZING R175H OR Y220C MUTATION IN P53
#49COMPOSITIONS AND METHODS TARGETING THE NUCLEOTIDE FREE STATE OF RAS TO BLOCK ONCOGENIC SIGNALING AND TRANSFORMATION
#50Detection of anti-p53 antibodies
#51RAF1 FUSIONS
#52HLA class II-restricted t cell receptors against mutated RAS
#53TUMOR CELL-DERIVED MICROVESICLES
#54CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
#55Method for treating cancer based on expression levels of translationally controlled tumor protein (TCTP)
#56NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
#57Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#58Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
#59Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#60NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
#61Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#62Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#63Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#64Anti-mutated KRAS T cell receptors
#65HSP90 COMBINATION THERAPY
#66Pancreatic cancer detection method and pancreatic cancer detection kit
#67Anti-kit antibodies and uses thereof
#68MACROPINOCYTOSIS IN CANCER
#69USE OF TROP-2 AS PREDICTIVE MARKER OF RESPONSE TO ANTI-TUMOR THERAPY BASED ON INHIBITORS OF CD9, AKT AND MOLECULES OF THE TETRASPANIN SIGNALLING NETWORK
#70Charged mass labeling system
#71High affinity monoclonal antibodies targeting glypican-2 and uses thereof
#72Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#73Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#74PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
#75DATA PROCESSING SYSTEM FOR IDENTIFYING A THERAPEUTIC AGENT
#76Micro-Array Devices for Capturing Cells in Blood and Methods of Their Use
#77Gremlin-1 antagonist for the prevention and treatment of cancer
#78CANCER EPIGENETIC PROFILING
#79Method for the prognosis and treatment of cancer metastasis
#80Method for evaluating multiple different genes of interest
#81PANDA AS NOVEL THERAPEUTIC
#82T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2
#83Method for treating neoadjuvant chemotherapy-induced metastasis
#84Protein sensor and manufacturing method thereof
#85MATERIALS AND METHODS FOR DETECTING FUSION PROTEINS
#86Polypeptide-antibody complexes and uses thereof
#87Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
#88PREDICTING RESPONSE TO ALVOCIDIB BY MITOCHONDRIAL PROFILING
#89DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPases
#90ANTIBODIES TO M(H)DM2/4 AND THEIR USE IN DIAGNOSING AND TREATING CANCER
#91SHON AS A PROGNOSTIC BIOMARKER FOR CANCER AND AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY
#92Methods of BH3 profiling
#93Biomarker for HER2-positive cancer and anti-HER2 therapy and applications thereof
#94Sulfonylamide compounds as CDK2 inhibitors
#95Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#96BENZENESULFONAMIDE DERIVATIVES OF QUINOXALINE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN METHODS FOR TREATING CANCER
#97Methods and compositions for treating cancer using peptide nucleic acid-based agents
#98Immunoassay and antibodies for the detection of chromogranin A
#99Product and process for employing GC7 (N1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy
#100Eukaryotic translation initiation factors (EIFS) as novel biomarkers in head and neck squamous cell carcinoma (HNSCC)
#101Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#102MOLECULAR PROFILING FOR CANCER
#103Methods based on the detection of RAD51 foci in tumor cells
#104Radio-labelled antibody fragments for use in the prognosis, diagnosis of cancer as well as for the prediction of cancer therapy response
#105METHOD FOR DETERMINING PRESENCE OR ABSENCE OF RISK OF DEVELOPING CANCER
#106Anti-c-Met antibody and use thereof
#107Anti-epidermal growth factor receptor (EGFR) antibodies
#108Method of treating or preventing Ras-mediated diseases
#109Compositions and methods for detecting prostate cancer
#110Method for Predicting Effectiveness of Angiogenesis Inhibitor
#111RAF1 FUSIONS
#112Mutant human estrogen receptor-α and methods of use thereof
#113DILUENT FOR FLUORESCENT NANO PARTICLES, KIT FOR IMMUNOFLUORESCENT STAINING WHICH UTILIZES SAME, SOLUTION FOR IMMUNOFLUORESCENT STAINING, IMMUNOFLUORESCENT STAINING METHOD, AND GENE STAINING METHOD
#114T cell receptors recognizing HLA-CW8 restricted mutated KRAS
#115TUMOR CELL-DERIVED MICROVESICLES
#116Monoclonal antibodies against c-Met
#117Therapeutic agent for tumors identified by phosphorylation of proto-oncogene protein belonging to VAV family
#118IN VITRO METHOD FOR THE DIAGNOSIS OF LUNG CANCER
#119Diagnosis and treatment of lymphoproliferative disorders with PARP inhibitors
#120METHODS OF INHIBITING CANCER STEM CELLS WITH HMGA1 INHIBITORS
#121Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#122Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#123Diagnostic and therapeutic methods for cancer
#124Residue-based pharmacophore method for identifying cognate protein ligands
#125Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
#126Cell response assay for cancer and methods of producing and using same
#127Target genes in MYC-driven neoplasia
#128DISCOVERY AND VALIDATION OF CANCER BIOMARKERS USING A PROTEIN ANALYSIS METHODOLOGY TO ANALYZE SPECIMENS
#129Cancer Diagnostic Metastasis Panel
#130ANALYSIS OF RESPONSE TO THERAPEUTICS IN CANCER
#131Methods and compositions for treating cancer using peptide nucleic acid-based agents
#132Predicting response to alvocidib by mitochondrial profiling
#133Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#134Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#135ANTI- EGFR CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF
#136Compositions and methods to detect head and neck cancer
#137ERG monoclonal antibodies
#138AKT-SPECIFIC CAPTURE AGENTS, COMPOSITIONS, AND METHODS OF USING AND MAKING
#139HDAC1,2 inhibitors and methods of using the same
#140MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571
#141T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
#142Charged mass labeling system
#143METHODS OF TREATING A NEUROENDOCRINE TUMOR
#144BCR-ABL truncation mutations
#145Methods of treating by administering anti-kit antibodies
#146Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#147METHODS OF EVALUATING A CELLULAR SAMPLE FOR HER-2/NEU EXPRESSION AND COMPOSITIONS FOR PRACTICING THE SAME
#148METHODS OF IDENTIFYING AND TREATING IMMUNE CHECKPOINT INHIBITOR-RESPONSIVE NEOPLASMS AND CELLS, TRANSGENIC ANIMALS AND KITS FOR USE THEREIN
#149HLA class II-restricted T cell receptors against mutated RAS
#150System for detecting infection in synovial fluid
#151Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#152HAAH and MMP-9 are Complementary Cancer Biomarkers and Predictors of Metastasis when Combined
#153Lipid scavenging in Ras cancers
#154T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
#155Predicting response to alvocidib by mitochondrial profiling
#156STABILIZED PEPTIDE FRAGMENTS FROM PROTOCADHERIN FAT1 AS CANCER BIOMARKERS
#157DETECTION OF ANTI-p53 ANTIBODIES
#158BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
#159Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#160Cyclic peptide binder against oncogenic K-Ras
#161METHOD FOR DETECTING CIRCULATING TUMOR CELLS AND USES THEREOF
#162MACROPINOCYTOSIS IN CANCER
#163Nano-Devices for Detection and Treatment of Cancer
#164Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#165In vitro selection of formaldehyde cross-linking aptamers
#166Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers
#167Micro-array devices for capturing cells in blood and methods of their use
#168EX VIVO LIQUID BIOPSY
#169MOLECULAR PROFILING FOR CANCER
#170Method of treating or preventing Ras-mediated diseases
#171RADIO-LABELLED ANTIBODY FRAGMENTS FOR USE IN THE PROGNOSIS, DIAGNOSIS OF CANCER AS WELL AS FOR THE PREDICTION OF CANCER THERAPY RESPONSE
#172HDAC1,2 INHIBITORS AND METHODS OF USING THE SAME
#173Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#174Method for the prognosis and treatment of cancer metastasis
#175DILUENT FOR FLUORESCENT NANO PARTICLES, KIT FOR IMMUNOFLUORESCENT STAINING WHICH UTILIZES SAME, SOLUTION FOR IMMUNOFLUORESCENT STAINING, IMMUNOFLUORESCENT STAINING METHOD, AND GENE STAINING METHOD
#176Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
#177A METHOD FOR PROGNOSIS OF OVARIAN CANCER, PATIENT'S STRATIFICATION
#178Auto-active and intracellular mutant of MET
#179MONOCLONAL ANTIBODIES AGAINST C-MET
#180MONOCLONAL ANTIBODIES AGAINST C-MET
#181Anti-HER3 antibodies and uses of same
#182Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
#183Anti-mutated KRAS T cell receptors
#184Microplate and in vitro diagnostic kit for HPV 16/E7 oncoprotein detection and preparation method thereof
#185Biomarker RNF6 for colorectal cancer
#186Diagnosis and treatment of breast cancer
#187BIOMARKERS FOR CANCER DIAGNOSIS AND PROGNOSIS AND METHOD FOR USING THEREOF
#188DIAGNOSIS OF CANCER
#189NOVEL ANTI-CXCR4 ANTIBODY AND ITS USE FOR THE DETECTION AND DIAGNOSIS OF CANCER
#190Anti-epidermal growth factor receptor (EGFR) antibodies
#191Discovery and validation of cancer biomarkers using a protein analysis methodology to analyze specimens
#192Methods of inhibiting cancer stem cells with HMGA1 inhibitors
#193TERT fusions
#194KRAS MUTATIONS AND RESISTANCE TO ANTI-EGFR TREATMENT
#195Method For Predicting Effectiveness Of Angiogenesis Inhibitor
#196Anti-EGFR conformational single domain antibodies and uses thereof
#197ANTI-ErbB2 ANTIBODIES
#198Methods of determining cellular chemosensitivity
#199SRM/MRM Assays
#200Methods of treating a kit-associated cancer by administering anti-kit antibodies
#201Method for inhibiting intracellular activated RAS using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof
#202CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME
#203Biomarker SPAG5
#204BIOMARKERS FOR RESPONSE TO EZH2 INHIBITORS
#205RAF1 fusions
#206METHODS, ASSAYS, AND SYSTEMS RELATING TO SAKT
#207SRM/MRM Assay for the GTPase KRas Protein (KRas)
#208Immunoassay and antibodies for the detection of chromogranin A
#209T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
#210Hybridoma cell lines (my-C-CC0C2-235-3H8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein C (C-protein, MYBPC3, CMYBP-C or MY-C)
#211RAF gene fusions
#212METHOD FOR DETECTING CARCINOGENESIS IN THE UTERINE CERVIX
#213BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
#214TREATMENT OF TUMORS EXPRESSING MUTANT P53
#215NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
#216ISOLATION AND DETECTION OF CANCER CELLS
#217ASYMMETRIC INTERFERING RNA COMPOSITIONS THAT SILENCE K-RAS AND METHODS OF USES THEREOF
#218SHON AS A PROGNOSTIC BIOMARKER FOR CANCER AND AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY
#219NSD3 INHIBITORS FOR TREATMENT OF CANCERS
#220METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, CLASSIFICATION, AND TREATMENT OF CANCER
#221Expression of ETS related gene (ERG) and phosphatase and tensin homolog (PTEN) correlates with prostate cancer capsular penetration
#222Quantifying Her2 protein for optimal cancer therapy
#223Methods and compositions for treating cancer using peptide nucleic acid-based agents
#224MET-BINDING AGENTS AND USES THEREOF
#225Detection method for NTRK3 fusion
#226Benzenesulfonamide derivatives of quinoxaline, pharmaceutical compositions thereof, and their use in methods for treating cancer
#227Predicting response to alvocidib by mitochondrial profiling
#228Biomarker for MELK activity and methods of using same
#229Diagnostic/prognostic marker and therapeutic target for cancer
#230Cyclic peptide binder against oncogenic K-Ras
#231MULTIFUNCTIONAL METAL NANOSTRUCTURE AND METHOD FOR PRODUCING SAME
#232Akt-specific capture agents, compositions, and methods of using and making
#233Tumor cell-derived microvesicles
#234Methods of BH3 profiling
#235Method of selectively inhibiting Ras-mediated tumor growth in humans
#236Activated HER3 as a marker for predicting therapeutic efficacy
#237Oncogene associated with human cancers and methods of use thereof
#238METHOD FOR THE PROGNOSIS AND TREATMENT OF CANCER METASTASIS
#239Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571
#240Lipid scavenging in Ras cancers
#241BIOMARKERS FOR PREDICTING RESPONSE OF DLBCL TO TREATMENT WITH A BTK INHIBITOR
#242Drug selection for non-small cell lung cancer therapy
#243Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
#244Process for detection and optional quantification of an analyte
#245INACTIVE N-ACETYLATED-ALPHA-LINKED ACIDIC DIPEPTIDASE-LIKE PROTEIN 2 (NAALADL2) AS A THERAPEUTIC AND DIAGNOSTIC TARGET
#246Monoclonal antibodies against c-Met
#247Methods of inhibiting cancer stem cells with HMGA1 inhibitors
#248Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148
#249Methods and compositions for screening and detecting biomarkers
#250Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression
#251Tumor cell-derived microvesicles
#252Method for the prognosis and treatment of cancer metastasis
#253T cell receptor-like antibodies specific for a WTI peptide presented by HLA-A2
#254Phosphorylated Akt-specific capture agents, compositions, and methods of using and making
#255Anti-phospho-Akt antibodies
#256IMMUNOLOGICAL COMPOSITIONS AS CANCER BIOMARKERS AND/OR THERAPEUTICS
#257RAF gene fusions
#258Biomarker SPAG5
#259FUSION GENE OF CEP55 GENE AND RET GENE
#260MARKERS ASSOCIATED WITH HUMAN DOUBLE MINUTE 2 INHIBITORS
#261ANTIBODIES SPECIFIC TO E6 PROTEINS OF HPV AND USE THEREOF
#262COMPOSITIONS AND METHODS FOR DIAGNOSIS AND THERAPY OF DISORDERS RELATED TO ALTERATIONS OF MYH9
#263COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS
#264Methods and compositions for identifying, diagnosing, and treating neuroblastoma
#265Anti-c-met antibodies
#266MULTIFUNCTIONAL METALLIC NANOSTRUCTURE AND METHOD FOR MANUFACTURING THE SAME
#267BLID; a novel protein domain for interaction with the Bcl-2 family of proteins. Applications in oncology
#268TEST FOR DIAGNOSING RESISTANCE TO AZACITIDINE
#269MODULATION OF LINE-1 REVERSE TRANSCRIPTASE
#270DETECTION OF PROSTATE AND BLADDER CANCER
#271Antibodies for oncogenic strains of HPV and methods of their use
#272Substituted quinoxalines as B-raf kinase inhibitors
#273Systems and methods for anti-PAX8 antibodies
#274Monoclonal antibodies and diagnostic uses thereof
#275Anaplastic lymphoma kinase (ALK) as an oncogene capable of transforming normal human cells
#276Aptamer which selectively binds to ERBB2 receptor and uses thereof
#277BIOMARKERS OF MIR-34 ACTIVITY
#278SMALL SPECIMEN STAINING AND DIAGNOSING OF CELLS
#279ERG MONOCLONAL ANTIBODIES
#280Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
#281HSP90 COMBINATION THERAPY
#282Akt-specific capture agents, compositions, and methods of using and making
#283METHODS OF PREDICTING PROGNOSIS IN CANCER
#284T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
#285Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor
#286IDENTIFICATION OF CANCER STEM CELL MARKERS AND USE OF INHIBITORS THEREOF TO TREAT CANCER
#287CELL RESPONSE ASSAY FOR CANCER AND METHODS OF PRODUCING AND USING SAME
#288Compositions And Methods For Modulating Apoptosis
#289Method of screening of therapeutic agents for K-Ras mutant driven cancers
#290KRAS MUTATIONS AND RESISTANCE TO ANTI-EGFR TREATMENT
#291NOVEL ANTI-cMET ANTIBODY
#292Compositions and methods for detecting cancer
#293Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
#294Differential Diagnosis Of Cancer And Other Conditions Based On Expression Of p63
#295Markers associated with human double minute 2 inhibitors
#296BIOMARKERS FOR PREDICTING SENSITIVITY TO CANCER TREATMENTS
#297DRUG SELECTION FOR MALIGNANT CANCER THERAPY USING ANTIBODY-BASED ARRAYS
#298P28GANK monoclonal antibody and peptides for preparation thereof and use thereof
#299TUMOR CELL-DERIVED MICROVESICLES
#300Methods of determining cellular chemosensitivity